Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio Inc (ANAB) is a clinical-stage biotechnology company advancing antibody therapies for autoimmune and inflammatory diseases through its proprietary discovery platforms. This page aggregates official news releases, clinical trial milestones, and strategic partnership announcements directly from the company and verified sources.
Investors and researchers will find timely updates on pipeline developments, regulatory progress, and financial disclosures, including updates on checkpoint agonists and cytokine antagonists in clinical testing. The curated collection serves as a centralized hub for tracking the company’s progress in immunology therapeutics and antibody discovery.
Content spans phase trial results, licensing agreements, and technology innovations related to the shm-xel platform. Bookmark this page for efficient access to AnaptysBio’s latest advancements in developing treatments for conditions like atopic dermatitis and ulcerative colitis.
AnaptysBio, a clinical-stage biotechnology firm focusing on immunology therapeutics, has appointed Dr. Rita Jain to its Board of Directors, effective immediately, following the resignation of Laura J. Hamill. Dr. Jain brings extensive expertise in rheumatology and drug development, which is expected to enhance the board’s capabilities during a critical growth phase for the company. Dr. Jain is involved in advancing immune cell modulators for autoimmune disorders, particularly in guiding Phase 2 clinical trials targeting PD-1 and BTLA checkpoint agonists. AnaptysBio’s portfolio includes several candidates in late-stage development, indicating a strong focus on addressing unmet medical needs in autoimmune diseases.
AnaptysBio, Inc. (Nasdaq: ANAB) announced significant interim results from the RUBY phase 3 trial of Jemperli (dostarlimab-gxly) for advanced endometrial cancer. The trial showed a 72% reduction in the risk of disease progression or death in the dMMR/MSI-H population, and a 36% reduction in the overall patient population. The results were published in The New England Journal of Medicine and presented at the ESMO Virtual Plenary. GSK aims for regulatory submissions in the first half of 2023. AnaptysBio anticipates potential royalties from Jemperli, particularly following these promising results.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
